ArticleJAMA2021
Two Models of Legalization of Psychedelic Substances: Reasons for Concern.
Article in JAMA, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2023Pooled it
- From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical Practice.Pharmacology research & perspectives · 2026Article
- Innovations in health behavior research: Current status and strategic future directions.Experimental and clinical psychopharmacology · 2026Review
- Ethical Issues and Recommendations in Psychedelic Research and Practice: A Scoping Review.Journal of bioethical inquiry · 2026Article
- Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper.European psychiatry : the journal of the Association of European Psychiatrists · 2025Article
- Geographical Differences in Self-Reported Past 12-Month Drug Use: Results from the NDEWS Rapid Street Reporting, 2021-2023.Substance use & misuse · 2025Article
- The influence of stakeholder interests on safety outcome reporting in psychedelic research and implications for science communication.Trends in psychiatry and psychotherapy · 2025Article
- Review
- A Perspective on Psychedelics as Treatments for Addictions.Journal of studies on alcohol and drugs · 2024Article
- A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia.The Australian and New Zealand journal of psychiatry · 2024Review
- National and regional trends in seizures of shrooms (psilocybin) in the United States, 2017-2022.Drug and alcohol dependence · 2024Article
- Long-term benefits to psychological health and well-being after ceremonial use of Ayahuasca in Middle Eastern and North African immigrants and refugees.Frontiers in psychiatry · 2024Article
- The safety of supported psilocybin use in Oregon.Nature medicine · 2024Article
- The Ethics of Risk Prediction for Psychosis and Suicide Attempt in Youth Mental Health.The Journal of pediatrics · 2023Review
- Reducing the Harms of Nonclinical Psychedelics Use Through a Peer-Support Telephone Helpline.Psychedelic medicine (New Rochelle, N.Y.) · 2023Article
- Ethical principles of traditional Indigenous medicine to guide western psychedelic research and practice.Lancet regional health. Americas · 2023Review
- Drug scheduling limits access to essential medicines and should be reformed.Nature medicine · 2023Article
- Psychedelic Drug Legislative Reform and Legalization in the US.JAMA psychiatry · 2023Article
- The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials.Innovations in clinical neuroscience · 2023Review
- Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice.Transcultural psychiatry · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.